caa a22 4500 465789587 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171846 doi (NATIONALLICENCE)springer-10.1007/BF00171846 Phase II study of Fenretinide (N-[4-Hydroxyphenyl]retinamide) in advanced breast cancer and melanoma [Elektronische Daten] [Manuel Modiano, William Dalton, Scott Lippman, Leonard Joffe, Ann Booth, Frank Meyskens Jr.] Summary: Retinoids, the natural and synthetic analogs of vitamin A, are growth-inhibiting and differentiation-inducing agents and show clinical promise as chemopreventive and antineoplastic agents. Fenretinide, a new synthetic retinoid, has antitumor activity in certain in vitro and in vivo model systems and was relatively nontoxic in phase I trials. Based on these data, we designed a phase II study of Fenretinide involving 31 patients with advanced breast cancer [15] and melanoma [16], two cancers shown to be responsive to this agent in preclinical models. Fenretinide was inactive in patients with advanced disease. Toxicity was mild, and reversible. Mucocutaneous side effects occurred in 16 (52%) patients. Nyctalopia developed in three patients one of whom developed decreased B-wave amplitude of the scotopic electroretinogram. The minimal toxicity and significant activity in preclinical studies make this an attractive agent for future breast cancer chemoprevention studies. Kluwer Academic Publishers, 1990 fenretinide nationallicence retinoids nationallicence melanoma nationallicence breast cancer nationallicence Modiano Manuel Section of Hematology/Oncology, Department of Internal Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA aut Dalton William Section of Hematology/Oncology, Department of Internal Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA aut Lippman Scott The University of Texas MD Anderson Cancer Center, Houston, Texas, USA aut Joffe Leonard Department of Ophthalmology, University of Arizona Cancer Center, Tucson, Arizona, USA aut Booth Ann Section of Hematology/Oncology, Department of Internal Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA aut Meyskens Jr. Frank University of California Irvine Cancer Center, Orange, California, USA aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 317-319 0167-6997 8:3<317 1990 8 10637 https://doi.org/10.1007/BF00171846 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171846 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Modiano Manuel Section of Hematology/Oncology, Department of Internal Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Dalton William Section of Hematology/Oncology, Department of Internal Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Lippman Scott The University of Texas MD Anderson Cancer Center, Houston, Texas, USA aut NATIONALLICENCE 700 1- Joffe Leonard Department of Ophthalmology, University of Arizona Cancer Center, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Booth Ann Section of Hematology/Oncology, Department of Internal Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA aut NATIONALLICENCE 700 1- Meyskens Jr Frank University of California Irvine Cancer Center, Orange, California, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 317-319 0167-6997 8:3<317 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer